57 Search Results

q=Sarcoma

Search Again


Teresa Kim , MD

Email: tkim5@uw.edu

Phone: (206) 221-8290

Dr. Kim is a Surgical Oncologist and UW Acting Assistant Professor of Surgery, with expertise in the surgical management of sarcomas, melanomas, and other cancers of the soft tissue, skin, and gastrointestinal tract. Her primary sites of practice are the University of Washington Medical Center, where she operates, and the Seattle Cancer Care Alliance, where she sees patients in clinic. Dr. Kim is a dedicated cancer surgeon who works with a multidisciplinary team of experts to provide individualized and outstanding care. She is also investigating the body’s immune response to cancer and new treatment approaches that combine standard therapies, such as surgery, radiation, and chemotherapy, with novel treatments such as immunotherapy.

View Bio

Linda Ko , PhD, MPH

Email: lko@fhcrc.org

Phone: (206) 667-7182

Dr. Ko is the director of the Center for Health Communication Intervention (CHEALCI). She is a behavioral scientist with expertise in the development, testing, and evaluation of health communication strategies. Her work draws from the discipline of communication, marketing, social epidemiology, and social and behavioral sciences. Her research aims to understand community behavior within the socio-cultural context, develop interventions that will address those behaviors and translate knowledge through community-based participatory research.

View Bio

George Laramore , PhD, MD

Email: georgel@u.washington.edu

Phone: (206) 598-4110

Dr. Laramore specializes in treating patients for salivary gland tumors, head and neck cancer, sarcoma of the soft tissue and bone, and genitourinary tumors particularly prostate cancer. He is also lead investigator for several clinical trials evaluating radiation therapy in several types of cancers. He also has an interest in the use of boron neutron capture therapy (BNCT) to treat certain types of cancer.

View Bio

Yajuan Liu , PhD

Email: yajuan@uw.edu

Dr. Liu's research lab is currently focused on the following four projects: (1)Developing DNA sequence-based characterization of breakpoints of chromosome translocations/inversions in cancer using next generation sequencing. (2) Identifying new markers for Hepatitis C-associated hepatocellular carcinoma. (3) Correlating genetic alterations detected using genomic microarray and next generation sequencing with histology and clinical outcome in melanocytic neoplasms. (4) Use of genomic microarray analysis to rule in/out oncocytoma of the kidney in needle core biopsies. Dr. Liu's main goals are to identify cancer biomarkers and novel therapeutic targets and to develop molecular diagnostics using both conventional genetics methods and new genomic approaches to aid in precision diagnostics for personalized care.

View Bio

Simon Lo , MD; Ch.B; FACR

Email: simonslo@uw.edu

Dr. Lo is a nationally and internationally renowned clinician, scholar and expert in advanced stereotactic radiation therapy techniques in brain tumors and tumors outside the CNS. In addition to his extensive expertise in CNS tumors, Dr. Lo has also been on the leading edge of expanding image-guided stereotactic radiation techniques beyond the brain to multiple other tumor sites, and his work has set the standard in clinical applications and care of patients in this area. He has made major contributions to the advancement of these innovative treatment techniques, translating them and increasing their efficacy and therapeutic ratio.

View Bio

Elizabeth Loggers , MD, PhD

Email: eloggers@seattlecca.org

Phone: (206) 288-6975

Dr. Loggers is medical director for Palliative Care and a medical oncologist who cares for adults with sarcoma.

View Bio

Manoj Menon , MPH, MD

Email: mmenon@fhcrc.org

Dr. Menon is a medical oncologist and hematologist. He has research interests in malaria, malignant hematology, global health, health services research and implementation science.

View Bio

Andrew Mhyre , PhD

Email: amhyre@fhcrc.org

Phone: (206) 667-3047

Dr. Mhyre's research is focused on the discovery of new treatment options for rare diseases. His work focuses on throughput screening, in vitro biology, medicinal chemistry, DMPK and in vivo biology to progress to IND filing.

View Bio

Wayne Monsky , MD, PhD

Email: wmonsky@uw.edu

Phone: 206 598-1454

Dr. Monsky is director of interventional radiology at the Harborview Medical Center and also provides clinical care at the UW Medical Center. He is a UW associate professor of radiology. He is an expert in all aspects of interventional radiology including minimally invasive therapies for cancer, uterine fibroids, deep venous thrombosis, and gastrointestinal bleeding. He also conducts research on novel approaches to treat solid malignancies, remove blood clots and the use of advanced ultrasound techniques to diagnose and treat a number of diseases, as a member of the Ultrasound-based Washington Molecular Imaging and Therapy Center. He has been integral to the development and optimization of a number of state-of-the-art novel medical devices.

View Bio

Polly Newcomb , PhD, MPH

Email: pnewcomb@fredhutch.org

Phone: (206) 667-3476

As a cancer epidemiologist, Dr. Newcomb focuses her research on the identification of modifiable risk factors for common cancers, particularly breast and colon cancer. Since many of these risk factors appear to have only modest magnitudes of effect, more precisely identifying susceptible individuals defined by genes, epigenetic changes, or personal characteristics such as body size may help direct investigations in the population, laboratory and clinic. She studies these risk factors and their relationship to survival after diagnosis and with longevity.

View Bio

Andrew Oberst , Ph.D.

Email: oberst@uw.edu

Phone: (206) 221-7316

Dr. Oberst's research focuses on understanding how different forms of cell death occur, and how they influence immune responses in vivo. Multicellular organisms are complex communities cooperating of cells, and the death of some cells is required for the community to survive and thrive. His work studies the effect of each type of cell death in vivo, with the goal of understanding their role in processes such as inflammation, autoimmunity, tumor suppression, and immune responses to pathogen infection.

View Bio

James Olson , MD, PhD

Email: jolson@fredhutch.org

Phone: (206) 667-7955

Dr. Olson's laboratory uniquely combines the disciplines of clinical, basic, and translational research to develop new and targeted treatments for pediatric brain tumors and other diseases. Tumor tissue directly from surgical resection is used to establish patient-derived primary cell lines and tumor lines that grow as brain xenografts in mice. These patient-derived cancer models are subjected to high throughput screening to identify novel therapeutic targets. We recently used a genome-wide RNAi screen to identify PHF5a as a novel gene required for glioblastoma (Hubert et. al., Genes and Development 27:1032-1045; 2013). This work showed that PHF5a helps with proper messenger RNA splicing in cancer cells and provides a lead for novel glioblastoma therapies. The Olson lab pioneered the clinical use of small cysteine-rich proteins called knottins or when it conjugated a fluorescent dye to chlorotoxin to develop 'Tumor Paint'. Tumor Paint accumulates in cancer cells and is used to help surgeons distinguish tumor from healthy brain tissue during surgery. It is currently in clinical trials. Building on this work, the Olson, Strong, Paddison, and Simon labs have developed a new peptide drug discovery platform at Fred Hutch. The 'optide' (optimized peptide) platform integrates advanced protein design in silico with a proprietary protein production platform to discover and develop drugs for cancer and neurologic diseases.

View Bio

Susan Parkhurst , PhD

Email: susanp@fredhutch.org

The Parkhurst lab is interested in the actions of both maternally and zygotically contributed gene products that govern proper embryonic development in Drosophila. Building tissues and organs during embryogenesis involves a series of exquisite morphogenetic processes including precisely orchestrated tissue contractions, foldings and migrations. Many of the naturally occurring epithelial movements that shape the embryo during morphogenesis are similar to those employed in the wound healing response and to cell behaviors in tumor progression. The Parkhurst lab uses developmental, genetic, cell biological, and molecular approaches to look at different regulatory mechanisms and pathways required for proper Drosophila embryonic development. Their current efforts are divided between studies of: (1) molecular and cellular mechanisms of single cell and multicellular (tissue) wound repair; (2) actin and microtubule cytoskeleton dynamics mediated by the Rho1 small GTPase and its effectors Wash, Capu, and Spire; and (3) nuclear architecture and organization.

View Bio

Warren Phipps , MD, MPH

Email: wtphipps@fhcrc.org

Dr. Phipps' research focuses on human herpesvirus-8 (HHV-8) virology and the pathogenesis of Kaposi sarcoma (KS), the most common HIV-associated malignancy worldwide. Specific areas of investigation include factors associated with KS presentation and treatment outcomes, as well as host and viral gene expression in KS tumors. Dr. Phipps serves as the Medical Director of the Uganda Cancer Institute / Hutchinson Center Cancer Alliance and oversees the program's research activities on infection-related cancers in Kampala, Uganda.

View Bio

Venu Pillarisetty , MD

Email: vgp@uw.edu

Phone: (206) 616-4924

Dr. Pillarisetty is a surgical oncologist who cares for patients with pancreas cancer and sarcomas. His clinical expertise is in surgical management of benign and malignant pancreatic and hepatobiliary disorders, as well as general surgical oncology.

View Bio

Stephen Polyak , PhD

Email: polyak@uw.edu

Phone: 206-897-5224

Dr. Polyak's research focuses on the interactions between cells and viruses, with emphasis on hepatitis C virus (HCV) and HIV. One focus of his molecular virology and cell biology laboratory involves characterizing innate antiviral and inflammatory responses to virus infection. He also has a program focusing on how natural products combat chronic inflammation. Current efforts are focused on the liver protective natural product silymarin, generically known as milk thistle extract, on hepatic inflammation. Another project focuses on how natural products like silymarin reduce chronic immune activation associated with HIV infection. Research on the synthetic antiviral compound known as Arbidol (a.k.a. Umifenovir) has revealed that the drug is a broad spectrum antiviral compound, which inhibits infection of cells by many viruses, including HCV, Kaposi's sarcoma-associated herpesvirus (KSHV), certain Arenaviruses, and Ebola virus.

View Bio

Colin Pritchard , MD, PhD

Email: cpritch@uw.edu

Phone: (206) 598-8400

Dr. Pritchard specializes in cancer molecular diagnostics development for precision medicine and microRNA as blood-based biomarkers and he helped to develop UW-OncoPlex (a molecular test which can inform diagnosis, prognosis, and/or treatment plans for patients). His research is focused on two main areas related to cancer molecular diagnostics: microRNA as blood-based biomarkers, and cancer molecular diagnostics development for precision medicine.

View Bio

Daniel Raftery , PhD

Email: draftery@uw.edu

Phone: (206) 543-9709

Dr. Raftery is an expert in the field of metabolomics, the study of small molecules involved in the metabolism of biological systems, cells, animals and humans. His research focuses on the development of advanced analytical tools and statistical methodologies for profiling metabolites in complex biological samples. He has applied these analytic approaches and demonstrated their utility for early detection of several types of cancer, as well as their utility in researching diabetes and heart disease.

View Bio

Ramesh Rengan , MD, PhD

Email: rengan@uw.edu

Phone: (206) 598-4100

Dr. Ramesh Rengan is the associate medical director at SCCA Proton Therapy, A ProCure Center. He is internationally known for his work in treating lung cancer, esophageal cancer, thoracic malignancies, and melanoma. He specializes in genitourinary tumors including prostate cancer.

View Bio